What Makes Us Unique

  • Our scientists have identified unique breath molecule signatures that correlate with insulin levels.
  • Our cutting-edge sensor platform seamlessly analyzes breath in real time and syncs with a smartphone application.
  • Empower yourself to monitor insulin levels effortlessly and manage diabetes risks without the hassle.

Khan, M.S. et al. (2022). “Breath biomarkers of insulin resistance in pre-diabetic Hispanic adolescents with obesity.” Sci Rep, 12(339).

Project Timeline

2020-2024
Biomarker Discovery

Identified breath biomarkers correlated with insulin levels. Established foundational research and technical feasibility.

2024-2025
Prototype Development

Utilize MN Innovation Fund to build and refine the Dia Breath prototype.

2025-2026
Prototype Validation

Conduct product trials to validate safety, efficacy, and market readiness.

2026-2027
Commercial Readiness

Launch Dia Breadth in the market with strategic partnerships and targeted marketing campaigns. 

Progress

Customer discovery

Conducted 10+ customer discovery interviews validating demand.

Vendor Engagement

Initiating vendor discussions for sensor acquisition and AI app development.

Lab Setup

Selected a space for the lab and in the process of acquiring lab equipments

Program Completion

completed the MN Launch VPD program and are actively exploring connections with MN-based incubators

Feasibility Studies

Roadmap milestone – Months 1-6: Focused on completing feasibility studies and demonstrating proof of concept

Market Readiness

Roadmap milestone – By Month 30, launch a full-scale market-ready product, achieving TRL 9 and commercialization goals.

Scroll to Top